Provectus Pharmaceuticals, Inc. Melanoma Version of PV-10 Completes Phase 2 and is Prepping for BTD

NEW YORK, Feb. 27, 2014 /PRNewswire/ -- Provectus Pharmaceuticals, Inc. (OTC: PVCT) The melanoma version of the drug is the closest to market release. Phase 2 data was finalized in October 2012 and the drug is being prepped for Breakthrough Therapy Designation (BTD) Drug Submission with the FDA and is in the final steps for approval.  Once submitted PVCT should receive a decision within 60 days of receipt of that request.

The breast and liver cancer versions of the drug have completed phase 1 trials and are being prepped for phase 2.

A full analyst research report written on Jan. 21, 2014 which entails Key features of the Global Pharmaceuticals Industry, Porter's Five Forces, U.S Food and Drug Administration's (FDA) Approval process, Product portfolio, Status of PV-10, value of the company and analyst summary. The comprehensive analyst research report can be viewed in its entirety with price target and analyst recommendation by using this link: http://bit.ly/AnalystResearchReportPVCT copy and paste to browser may be required

In a previous press release dated Feb. 18, 2014 we incorrectly stated that PV-10 melanoma version trial was underway. This press release was issued to correct this.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of companies mentioned to be materially different from the statements made herein.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. Information in this release is fact checked and produced on a best efforts basis by Osman Ghani, a CFA charterholder. An outsourced research services provider represented by Osman Ghani, CFA, provided Small Cap Street, LLC this article or report. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. Small Cap Street, LLC is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Osman Ghani, CFA. PVCT has not compensated Small Cap Street, LLC or Osman Ghani for the creation or dissemination of this report. Small Cap Street, LLC is the party responsible for issuing the press release and for hosting the full analyst report on smallcapir.com. Osman Ghani, Chartered Financial Analyst, is the author of research report. This information is submitted to increase awareness for mentioned companies to our subscriber base and the investing public.

If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected]. For any urgent concerns or inquiries, please contact us at [email protected].

NOT FINANCIAL ADVICE

Small Cap Street, LLC makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Small Cap Street, LLC is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming.  Small Cap Street, LLC has compensated Osman Ghani, CFA, two hundred and fifty dollars for the right to disseminate analyst report. No liability is accepted by Small Cap Street, LLC whatsoever for any direct, indirect or consequential loss arising from the use of this document. Small Cap Street, LLC expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Small Cap Street, LLC does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Small Cap Street, LLC